TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01411956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-minute video episode of patient education TV sitcom White Coats
Description: The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
Study: NCT04244786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
Study: NCT02045940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
Study: NCT01411956

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo video
Description: The control group watched a 25-minute patient education video on depression.
Study: NCT01984918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminder
Description: A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-SMS reminder
Description: No Stext message reminder via Short Message Service (SMS) will be sent
Study: NCT04309708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine pump infusion
Description: Patients with nimodipine pump infusion with pump infusion line and other infusion equipments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nimodipine pump infusion
Description: Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
Study: NCT02045940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
Study: NCT04244786

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention for participants who discontinued prior to randomization
Study: NCT03657888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Club Denmark (FCD)
Description: Participation in Family Club Denmark

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: Participants on the waiting list
Study: NCT01572038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
Study: NCT00489853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol Turbuhaler 320/9µg
Description: Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: budesonide/formoterol Turbuhaler 320/9µg
Description: Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol Turbuhaler 320/9µg
Description: Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol Turbuhaler 9µg
Description: Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: formoterol Turbuhaler 9µg
Description: Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol Turbuhaler 9µg
Description: Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 inhalation twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 inhalation twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 1 inhalation twice daily
Study: NCT00518908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 3.2 Vol % for postconditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 3.2 Vol % for postconditioning
Study: NCT02603809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 5 mg
Description: One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 10 mg
Description: Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
Study: NCT05342272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine taurine PVP gel
Description: At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
Study: NCT02603809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Study: NCT05342272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin
Description: At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
Study: NCT03239080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
Study: NCT02699567

Intervention type: OTHER
Intervention: No intervention
Study: NCT02603809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 50 mg
Description: One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 20 mg
Description: One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
Study: NCT02045940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
Study: NCT01396811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 33525
Description: Daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 14 days
Study: NCT04058860

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS monitoring
Description: Cerebral and somatic near-infrared spectroscopy (rScO2) measurements

Intervention type: DEVICE
Group type: OTHER
Intervention: Cox monitoring
Description: Cerebral autoregulation monitoring

Intervention type: DEVICE
Group type: OTHER
Intervention: Sublingual microscopy
Description: Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
Study: NCT02603809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
Study: NCT01012336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant/Ramosetron/Dexamethasone
Description: Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg.
Study: NCT02953990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMS Program
Study: NCT02397330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Study: NCT02699567

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT00246701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin
Study: NCT02397330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: ultrasound guided nerve blocks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound guided nerve blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Study: NCT04342104

Intervention type: OTHER
Intervention: Monitoring for aggravation
Description: Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP

Intervention type: OTHER
Intervention: Monitoring for aggravation
Description: Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP

Intervention type: OTHER
Intervention: Evaluate HACOR score effectivity in this patients
Description: Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure

Intervention type: OTHER
Intervention: Evaluate HACOR score effectivity in this patients
Description: Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
Study: NCT02094716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Foam 4%
Description: Topical application, whole-body treatment
Study: NCT00246701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Lovaza
Description: Simvastatin + Lovaza (omega-3-acid ethyl esters)
Study: NCT02652260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine - Blinded
Description: A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine - Open-Label
Description: A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine - Open-Label
Description: A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRIPLA^TM
Description: A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ATRIPLA™
Description: A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Doravirine, Tenofovir, Lamivudine
Description: A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
Study: NCT02391181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Azad
Description: Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer®
Description: Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study: NCT03576859

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: Peripheral venous blood is collected before liver transplantation and after restoration of liver function

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: Peripheral venous blood is collected before liver transplantation and after restoration of liver function
Study: NCT04102995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone injection low dose
Description: Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone injection high dose
Description: Subcutaneous (SC) administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Subcutaneous (SC) administration
Study: NCT03580980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol and ketamine
Description: intravenous paracetamol and ketamine followed by ketorolac

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal levobupivacaine
Description: an epidural injection of morphine and levobupivacaine through the caudal space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patient controlled analgesia by morphine
Study: NCT02919254

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet It Sport Shot
Description: Commercially available concentrated beetroot juice supplement intended for athletes.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet It Sport Shot
Description: Commercially available concentrated beetroot juice supplement intended for athletes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fruit juice cordial containing negligible nitrate
Study: NCT03562312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensive aerobe exercise
Description: Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low-intensive aerobe exercise
Description: Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
Study: NCT04010877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
Description: Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
Study: NCT01237613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artelon
Description: Artelon Tissue Reinforcement
Study: NCT02094716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Permethrin Foam 4%
Description: Topical application, whole-body treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Foam 5%
Description: Topical application, whole-body treatment
Study: NCT02806960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study: NCT02094716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Permethrin Foam 5%
Description: Topical application, whole-body treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical application, whole-body treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical application, whole-body treatment
Study: NCT02806960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study: NCT03282513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120 (Ivosidenib)
Description: Single 500 mg dose of AG-120 (Ivosidenib).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-120 (Ivosidenib)
Description: Single 500 mg dose of AG-120 (Ivosidenib).
Study: NCT03472781

Intervention type: OTHER
Intervention: No intervention. A retrospective case review
Description: No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
Study: NCT04072081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Treatment of in suit coronary lesions with drug-coated balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: Treatment of in suit coronary lesions with drug-eluting balloon